April 28, 2020 / 11:28 AM / a month ago

BRIEF-Clearside Biomedical Revises NDA Resubmission Timeline And XIPERE Commercial Deal With Bausch Health

April 28 (Reuters) - Clearside Biomedical Inc:

* CLEARSIDE BIOMEDICAL REVISES NDA RESUBMISSION TIMELINE AND XIPERE™ COMMERCIAL PARTNERSHIP WITH BAUSCH HEALTH

* CLEARSIDE BIOMEDICAL INC - CLEARSIDE NOW EXPECTS TO RESUBMIT XIPERE NDA IN Q4 OF 2020

* CLEARSIDE BIOMEDICAL INC - CLEARSIDE AND BAUSCH HEALTH HAVE AMENDED AND REVISED THEIR PARTNERSHIP FOR XIPERE

* CLEARSIDE - BAUSCH + LOMB GRANTED EXCLUSIVE OPTIONS FOR RIGHT TO COMMERCIALIZE XIPERE IN EUROPE,U.K.,AUSTRALIA,NEW ZEALAND, S.AMERICA & MEXICO

* CLEARSIDE BIOMEDICAL INC - IN AMENDED AGREEMENT, BAUSCH + LOMB HAS EXTENDED TIME ALLOWED FOR CLEARSIDE TO OBTAIN XIPERE APPROVAL IN UNITED STATES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below